Clinical Trial

MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The main purpose of the study is to evaluate the safety and efficacy of MDN-001 injection(Yttrium-90 Microsphere Injection)in the treatment of unresectable hepatocellular carcinoma. Other purposes of this study include assessment of the effect of treatment on overall survival, the length of time it takes for the disease to worsen, if and how the treatment affects the patient's quality of life, and if and how the cancer responds to the treatment.
Trial Details
NCT Number NCT07391839
Lead Sponsor Suzhou Mednovo Yi Medical Technology Co., Ltd.
Conditions Hepatoma, Unresectable Hepatocellular Carcinoma (HCC)
Enrollment 40 participants
Start Date 2025-08-04
Primary Completion 2026-08-30 (estimated)
Study Completion 2027-05-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-06